Cefiderocol for Stenotrophomonas maltophilia Infections
Cefiderocol is an effective treatment option for Stenotrophomonas maltophilia infections, particularly when trimethoprim-sulfamethoxazole (TMP-SMX) resistance is present or when TMP-SMX has failed, with a standard adult dosing regimen of 2 grams IV every 8 hours infused over 3 hours, adjusted for renal function.
FDA-Approved Indication and In Vitro Activity
While cefiderocol is not yet FDA-approved specifically for S. maltophilia infections, the FDA drug label explicitly states that at least 90% of S. maltophilia isolates exhibit an in vitro MIC less than or equal to the susceptible breakpoint for cefiderocol 1. The label notes that "the efficacy of FETROJA in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials" 1, but acknowledges its potent in vitro activity.
Importantly, the FDA label confirms that cefiderocol is active in vitro against S. maltophilia containing metallo-carbapenemase (L1) and serine beta-lactamases (L2) 1, which are the primary resistance mechanisms in this organism.
Standard Adult Dosing Regimen
The recommended adult dose is 2 grams IV every 8 hours, administered as a 3-hour infusion 1. This is the dosing regimen used in phase III clinical trials and supported by pharmacodynamic data.
Renal Dose Adjustments (Critical)
Cefiderocol requires dose adjustment based on creatinine clearance (CrCl):
- CrCl 60-119 mL/min: 2 g IV every 8 hours
- CrCl 30-59 mL/min: 1.5 g IV every 8 hours
- CrCl 15-29 mL/min: 1 g IV every 8 hours
- CRRT patients: Dosing based on effluent flow rate 1
- Augmented renal clearance (CrCl ≥120 mL/min): 2 g IV every 6 hours 1
Monitor renal function regularly during therapy as it may change, requiring dose adjustments 1.
Clinical Evidence Supporting Use
Guideline Recommendations for S. maltophilia
The most relevant guideline evidence comes from the German Society of Hematology guidelines, which state: "In patients with suspected or documented S. maltophilia pneumonia, early antimicrobial intervention with high-dose TMP/SMX (15-20 mg/kg/day of trimethoprim) is recommended (B-II). In individual patients, tigecycline-based treatment may be an appropriate alternative (C-II)" 2.
However, these guidelines predate cefiderocol's availability (2015) and note that "in vitro susceptibility may not predict clinical efficacy of antimicrobial agents in S. maltophilia infections" 2, highlighting the historical challenge with this pathogen.
Real-World Clinical Data
Recent multicenter real-world evidence demonstrates cefiderocol's effectiveness:
- Clinical cure achieved in 64.3% of patients with S. maltophilia infections 3
- Microbiological eradication in 75% of cases 3
- 30-day mortality of 21.4% in a cohort with median Charlson Comorbidity Index of 5 3
- No cefiderocol-related adverse events reported 3
- Particularly effective when TMP-SMX resistance was present (35.7% of isolates) 3
Microbiological and Animal Model Data
Cefiderocol demonstrates exceptional in vitro activity:
- MIC50: 0.063 μg/mL; MIC90: 0.25 μg/mL against 217 S. maltophilia clinical isolates 4
- Active against TMP-SMX-resistant strains (MIC 0.125 μg/mL) 4
- In neutropenic mouse lung infection models, cefiderocol (30-100 mg/kg) showed significant, dose-dependent reduction in lung bacterial counts 4
- Only antibiotic tested that showed significant effect against TMP-SMX-resistant S. maltophilia in animal models 4
When to Use Cefiderocol for S. maltophilia
Primary Indications:
- TMP-SMX resistance documented (first-line alternative)
- TMP-SMX treatment failure despite susceptibility
- TMP-SMX contraindicated (allergy, severe renal impairment, drug interactions)
- Severe infections requiring rapid bactericidal activity (pneumonia, bloodstream infections)
- Polymicrobial infections where broader coverage needed (42.9% of cases in real-world data) 3
Site-Specific Considerations:
Pneumonia/Respiratory Infections: Most common indication (50% of cases) 3. Cefiderocol achieves therapeutic concentrations in epithelial lining fluid (3.1-20.7 mg/L at end of infusion) 1. Animal models specifically demonstrate efficacy in lung infections 4.
Bloodstream Infections: Successfully used for catheter-associated BSI, particularly when combined with device removal 5. Consider combination therapy with levofloxacin for biofilm-associated infections 5.
CNS Infections: Case report demonstrates CSF penetration 116-131-fold above MIC with plasma-to-CSF ratio of 16.6-25.7% 6. Standard dosing (2 g every 8 hours) achieved sustained therapeutic CSF concentrations 6.
Monotherapy vs. Combination Therapy
Cefiderocol monotherapy is appropriate for most S. maltophilia infections based on available evidence 7, 6, 3. However, consider combination therapy in specific scenarios:
- Biofilm-associated infections (e.g., catheter-related BSI): Add levofloxacin 5
- Severe hemorrhagic pneumonia: Levofloxacin may have superior lung penetration 8
- After TMP-SMX failure with retained device: Combination with levofloxacin plus device removal 5
The 2022 ESCMID guidelines note that for multidrug-resistant Gram-negative bacteria, lacking evidence, they cannot recommend for or against combination therapy with cefiderocol 9, suggesting monotherapy is reasonable when the organism is susceptible.
Treatment Duration
- Pneumonia: 7-14 days based on clinical response 7, 3
- Bloodstream infections: Minimum 14 days; 26 days reported in complex case with cure 6
- CNS infections: 26 days in successful case report 6
Monitor clinical response closely and adjust duration based on source control, immune status, and resolution of infection markers.
Critical Pitfalls to Avoid
Failure to adjust for renal function: Cefiderocol is 90.6% renally excreted unchanged 1. Inadequate dose adjustment risks treatment failure or toxicity.
Not monitoring for augmented renal clearance: Young, critically ill patients may have CrCl ≥120 mL/min requiring increased dosing frequency (every 6 hours) 1.
Assuming in vitro susceptibility guarantees clinical success: Historical data shows this is not always true for S. maltophilia 2, though cefiderocol appears more reliable.
Using 1-hour infusion instead of 3-hour: Pharmacodynamic studies show 3-hour infusion increases the percent time above MIC compared to 1-hour infusion 1.
Ignoring source control: Device removal critical for catheter-associated infections 5.
Adverse Effects
Cefiderocol is well-tolerated with a safety profile comparable to other cephalosporins 10. Minor adverse effects include gastrointestinal symptoms and phlebitis 10. Real-world data shows no cefiderocol-related adverse events in S. maltophilia treatment cohorts 3.